High level expression of recombinant human erythropoietin having a modified 5′-UTR
US7423139B2 · kind B2 · utility
1Cited by
25References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 20, 2004 |
| Grant date | Sep 9, 2008 |
| Priority date | — |
| Expiry date | Jun 8, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an expression construct capable of producing high levels of erythropoietin in mammalian cells. More particularly, the expression construct includes an erythropoietin coding region fused to a unique 5′-UTR sequence and a truncated 3′-UTR. The present invention also provides methods of synthesizing large amounts of erythropoietin and in increasing serum erythropoietin level in individuals in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.